Received Mar 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | M4B34 | — |
came back for the 2nd dose in 11/Mar/2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 74-year-old female patient who received HAB (Twinrix) (batch number M4B34, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix (the 1st dose of Twinrix was administered to the patient back in September 2024). On 11-MAR-2025, the patient received the 2nd dose of Twinrix. On 11-MAR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: came back for the 2nd dose in 11/Mar/2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 11-MAR-2025 A pharmacist called to inform that a patient delayed their 2nd dose of Twinrix. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule.